Stay updated with breaking news from David Marek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL...
At the beginning of February, Moody’s confirmed the Czech Republic’s credit rating at Aa3 with a stable outlook. A credit rating is an important guide for investors, as it shows them the likelihood that loans will be repaid, which has a significant effect on the willingness of creditors to provide loans to the state or other entities. It also affects the terms of the loan, such as the interest rate. The higher the rating, the better creditors perceive the borrower and the more likely they will accede to cheaper loans. “Moody’s warning is the first shot, fiscal consolidation was quite...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer Myovant Sciences, Inc.April 5, 2021 GMT BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with...
Czech economists: Pandemic cost 350 billion crowns and 80,000 jobs
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ... Myovant Sciences, Inc.February 11, 2021 GMT ORGOVYX™ (relugolix) approved by the U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in onco...